SAN.PA - Sanofi
| Previous Close | 66.18 |
| Open | 66.19 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 65.94 - 66.57 |
| 52 Week Range | 24.97 - 87.65 |
| Volume | 1,906,393 |
| Avg. Volume | 8,095 |
| Market Cap | 82.32B |
| Beta | 0.84 |
| PE Ratio (TTM) | 9.97 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.03 (4.60%) |
| Ex-Dividend Date | 2018-05-11 |
| 1y Target Est | N/A |
- Motley Fool•15 hours ago
3 Warren Buffett Stocks With Dividend Yields Over 4%
But are these high-yielding stocks in the billionaire investor's portfolio smart picks for the rest of us?
- Motley Fool•2 days ago
Is This European Drug Stock Giant a Buy?
Here's an international healthcare stock to consider for your portfolio.
- Moody's•4 days ago
AI Sirona (Luxembourg) Acquisition S.a.r.l. -- Moody's assigns Al Sirona Acquisition (Zentiva) a first-time rating of B3; outlook stable
Moody's Investors Service, ("Moody's") has today assigned a first-time B3 corporate family rating (CFR) and a B3-PD Probability of Default Rating (PDR) to Al Sirona (Luxembourg) Acquisition S.a.r.l. ...
- Motley Fool•5 days ago
Don’t Ignore European Healthcare Stocks
International healthcare stocks could be a great fit for your portfolio.
- Oilprice.com•6 days ago
5 Companies To Watch As Marijuana Legalization Approaches
Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains
- TheStreet.com•6 days ago
Trump Administration Rolls Out Shaming as Drug Pricing Tool
President Trump took heat for being too soft on drug companies in a speech last week. The Centers for Medicare and Medicaid Services on Tuesday, May 15, rolled out revamped Drug Spending Dashboards that likely will put pressure on drug companies to lower prices. The newly designed dashboards show how much is spent in Medicare Part B, Medicare Part D and Medicaid for name-brand drugs.
- Zacks•6 days ago
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
- Bloomberg•7 days ago
Luxury Stocks Are Reshaping France's CAC 40
A year ago LVMH, the owner of luxury brand Louis Vuitton, became France’s biggest company by market value, a mantle energy giant Total SA and drugmaker Sanofi SA had shared for almost a decade. Kering SA was nowhere in sight. A more than 200 percent rally since the start of 2016, and more than 70 percent over the past 12 months, has now put the owner of “it bag” brands within shouting distance of the top five stocks in the CAC 40 Index.
- Oilprice.com•8 days ago
The Likely 5 Winners Of Canada’s Cannabis Boom
The marijuana market in North America is growing at an astounding rate, with investors who are in the know set to reap most of the rewards
- Simply Wall St.•8 days ago
Is Sanofi’s (NYSE:SNY) Balance Sheet Strong Enough To Weather A Storm?
Investors pursuing a solid, dependable stock investment can often be led to Sanofi (NYSE:SNY), a large-cap worth US$94.36B. Doing business globally, large caps tend to have diversified revenue streams andRead More...
- Reuters•14 days ago
France says Iran deal "not dead", Macron to contact Rouhani
France's foreign minister said on Wednesday the Iran deal was not dead despite U.S. President Donald Trump's decision to pull out, and French President Emmanuel Macron would speak to his Iranian counterpart Hassan Rouhani later in the day. Jean-Yves Le Drian told RTL radio that France wanted to stick to the nuclear accord that Tehran agreed with world powers in 2015 - a pact which he said Iran had honoured.
- Simply Wall St.•16 days ago
With A -24.41% Earnings Drop, Is Sanofi’s (EPA:SAN) A Concern?
Measuring Sanofi’s (ENXTPA:SAN) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations, whichRead More...
- Motley Fool•17 days ago
3 Reasons Regeneron Stock Could Start Climbing Again
It's been a rough few years, but things are looking up in more ways than one.
- Motley Fool•18 days ago
Are These Disappointing Drugs Back on Track to Billions?
Sales of these heart disease drugs have been lackluster so far, but that may not be the case for too much longer.
- Zacks•18 days ago
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
- Investor's Business Daily•19 days ago
Regeneron Topples Despite Surprising Beat For Blockbuster Eye Drug
Regeneron reported better-than-expected adjusted earnings of $4.76 a share. The biotech's revenue of $1.51 billion came in a little below some forecasts.
- Zacks•19 days ago
Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of SAN.PA earnings conference call or presentation 27-Apr-18 12:30pm GMT
Q1 2018 Sanofi SA Earnings Call
- Investor's Business Daily•21 days ago
Regeneron Is Undercutting Amgen In Cholesterol Drugs — Will It Help Share?
Regeneron slipped to a four-year low Tuesday — prodding rival Amgen to also dip — after announcing a deal to cut the net price of its cholesterol drug.
- Reuters•21 days ago
Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts
Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday. The drug, Praluent, has a list price of over $14,000 a year, but the new price, after discounts and double-digit rebates, is on the "low end" of a $4,500 to $6,600 range, Express Scripts Chief Medical Officer Steve Miller told Reuters. Praluent, given by injection, dramatically lowers bad LDL cholesterol and reduces the risk of heart attacks and death in high-risk heart patients.
- Reuters•22 days ago
Sanofi/Regeneron cut Praluent drug price in Express Scripts deal
Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription ...
- Forbes•22 days ago
Regeneron And Express Scripts Reach A Deal On Embattled Cholesterol Drug
This morning, the drug makers Regeneron and Sanofi are cutting the price they charge pharmacy benefit manager Express Scripts for their cholesterol medicine, Praluent. In return, Express Scripts will remove almost all restrictions on the medicine, and make it cheaper for patients. “I really hope this works because otherwise it's a bad message for everyone going forward,” says Steve Miller, Express Scripts’ chief medical officer.
- Bloomberg•22 days ago
Express Scripts to Ease Access to Costly Cholesterol Drug
A rare ceasefire has been declared in the battle over the nation’s drug prices. Express Scripts Holding Co., one of the biggest U.S. pharmacy-benefit managers, agreed to ease restrictions on a novel cholesterol-cutting therapy after its manufacturers, Regeneron Pharmaceuticals Inc. and Sanofi, lowered its $14,600-a-year price. The deal is the first struck since the March announcement by Regeneron and Sanofi that they would cut the price of their drug, Praluent, in exchange for better access to patients.
- CNBC•22 days ago
A $14,000 cholesterol drug gets a price cut as Regeneron, Sanofi strike deal with Express Scripts
Praluent's new price will be $4,500 to $8,000 per year, the range recommended in March by the Institute for Clinical and Economic Review.
